Condition: Breast Cancer · Sponsor: University Hospital, Basel, Switzerland
In this multicenter retrospective cohort study the aim is to determine the safety of omission of axillary lymph node dissection in patients with TNBC and HER2+ tumors with residual macrometastases (in the SLN/TAD/TAS or MARI node) after NAC.
This description comes directly from the study's public registry record.
Walter P. Weber, Prof. Dr. med. · +41 61 328 61 49 · walter.weber@usb.ch
Andy Schneider, PhD · +41 61 328 42 98 · andy.schneider@usb.ch
Always discuss trial participation with your own doctor first.
| Department Breast, Abdomen, Pelvis; Universitätsspital Basel | Basel, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07546695